7 completed, 4 terminated, 1 unknown, 1 withdrawn. 13 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 7, Terminated 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Terminated 2, Unknown 1 |
Follow urelumab: new trials by email Literature Review of urelumab trials Research Report on urelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors Urelumab + Nivolumab - Neoplasms | Phase 1 / Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 32 | 2019-01-30 | 2019-01-03 |
| Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer Nivolumab, Cabiralizumab, Urelumab - Cancer | Phase 1 | Completed | University of Chicago | 60 | 2018-03-15 | 2023-02-16 |
| Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study - Glioblastoma, Gliosarcoma | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 63 | 2016-08-24 | 2023-10-06 |
| Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors Urelumab, Nivolumab - Malignant Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 18 | 2015-11-06 | 2020-05-18 |
| A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma Elotuzumab, Lirilumab, Urelumab - Multiple Myeloma | Phase 1 | Completed | Bristol-Myers Squibb | 44 | 2014-12-09 | 2017-11-01 |
| An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Urelumab, Nivolumab - Advanced Solid Tumors, Advanced B-cell NHL | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 232 | 2014-09-29 | 2020-10-05 |
| Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Urelumab, Cetuximab - Colorectal Cancer, Head and Neck Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 66 | 2014-04-01 | 2017-04-19 |
| Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Urelumab, Rituximab - B-Cell Malignancies | Phase 1 | Completed | Bristol-Myers Squibb | 47 | 2013-03-01 | 2017-03-31 |
| Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Urelumab (BMS-663513) - Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Completed | Bristol-Myers Squibb | 124 | 2012-02-01 | 2017-04-19 |
| Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma AntiCD137, Ipilimumab - Melanoma | Phase 1 | Withdrawn | Bristol-Myers Squibb | 2010-11-01 | 2011-11-21 | |
| A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC) BMS-663513 - Non Small Cell Lung Cancer | Phase 1 | Terminated | Bristol-Myers Squibb | 35 | 2008-01-01 | 2009-09-04 |
| A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies BMS-663513 - Advanced Solid Malignancies | Phase 1 | Terminated | Bristol-Myers Squibb | 45 | 2007-09-01 | 2009-09-04 |
| Study of BMS-663513 in Patients With Advanced Cancer BMS-663513 - Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 115 | 2005-12-01 | 2015-10-12 |
Neoplasms (4) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Head and Neck Neoplasms (1) · Lymphoma, B-Cell (1) · Melanoma (1) · Multiple Myeloma (1)
Bristol-Myers Squibb (10) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Chicago (1)
United States (11) · Spain (4) · France (3) · Canada (2) · Germany (2) · Japan (1)
Jason Luke, MD (1) · Micheal Lim, MD (1)
PMID 38458639, PMID 41543348, PMID 42432293
2014 (1), UM1CA137443 (1)